Healthpeak PropertiesNYSE: PEAK

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors (GIST). The data will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1. Cogent also announced today a new Phase 2 clinical trial of bezuclastinib plus sunitinib in later line GIST patients, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC) and in collaboration with The Life Raft Group and Dana-Farber Cancer Institute.

Healthpeak (PEAK) closes its merger with Physicians Realty Trust, positioning it well to capitalize on the secular trends of the industry.

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced today that Scott Brinker, its President and Chief Executive Officer, is scheduled to present at the Citi 2024 Global Property CEO Conference. The presentation is scheduled for 11:40 a.m. Eastern Time on Tuesday, March 5, 2024. You can access the webcast by visiting our website at https://ir.healthpeak.com/news-events/default.

Healthpeak Properties: Undervalued With Strong Fundamentals

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.

Healthpeak Properties, Inc. (PEAK) Q4 2023 Earnings Call Transcript

Healthpeak's (PEAK) Q4 results outshine estimates on better-than-anticipated revenues. Same-store cash NOI for the total portfolio improves year over year.

While the top- and bottom-line numbers for Healthpeak (PEAK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Healthpeak Properties topped market expectations for fourth-quarter funds from operations (FFO) on Thursday, on the back of strong demand for its medical office and life science properties.